The Challenges of CVD Risk Reduction in T2D: What Do the Landmark Outcome Trials Teach Us About Cardioprotection in the Diabetic Patient? Hertzel C. Gerstein, MD, MSc, FRCPC - Program Chairman
Prevention of Cardiovascular Morbidity and Mortality in T2D with Oral Agents: A Checkered and Controversial History Vivian Fonseca, MD, FRCP
What Are the Known and Potential Effects of Insulin on Atherogenesis in T2D? Jorge Plutzky, MD, FACC
Reducing Glucose Levels in Patients With Proven CAD: Does It Matter What Strategy is Used? Richard W. Nesto, MD
New Frontiers in Cardioprotection: Does Early Insulin Therapy Reduce Cardiovascular Outcomes in Patients With Dysglycemia? Hertzel C. Gerstein, MD, MSc, FRCPC - Program Chairman
Interactive Panel Discussion: Question and Answer Session Faculty Panel
